Hydrochloric Acid

Hydrochloric Acid

SCHEMBL30002297

CC[C@H](N)C(=O)NCc1ccc(OCc2ccc(C(F)(F)F)cc2)cc1.Cl

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAOB known ✓ P27338 6/20 0.54
ACE known ✓ P12821 1/20 0.52
PPARG known ✓ P37231 1/20 0.50
MMP13 known ✓ P45452 1/20 0.45
MME P08473 1/20 0.52
CPA1 P15085 1/20 0.52
ACE2 Q9BYF1 1/20 0.52
FFAR1 O14842 3/20 0.50
PPARA Q07869 1/20 0.48
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
SLC6A5 Q9Y345 1/20 0.46
ADAMTS4 O75173 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30001570 0.88 MAOB (0.58) MAOBFFAR1ADAMTS4MMP13
SCHEMBL31441380 0.84 MME (0.54) MAOBMMEACECPA1ACE2
SCHEMBL30002045 0.83 MME (0.53) MAOBMMEACECPA1ACE2
Hydrochloric Acid SCHEMBL30002091 0.83 MAOB (0.56) MAOBFFAR1PPARGADAMTS4MMP13
SCHEMBL30001612 0.82 MAOB (0.52) MAOBMMEACECPA1ACE2
SCHEMBL30794012 0.81 MAOB (0.61) MAOBFFAR1PPARGPPARASLC6A5
SCHEMBL21377326 0.80 MRGPRX4 (0.52) MAOBFFAR1PPARGPPARA
SCHEMBL30604549 0.80 MAOB (0.52) MAOBMMEACECPA1ACE2
Hydrochloric Acid SCHEMBL30002058 0.80 FFAR1 (0.50) MAOBFFAR1
SCHEMBL30001571 0.79 MME (0.52) MAOBMMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205195-A1 BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION AMTIXBIO CO., LTD. (KR) 2025-06-26 US claimed
US-20250034084-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS AMTIXBIO CO., LTD. (KR) 2025-01-30 US claimed
US-20250034083-A1 METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES AMTIXBIO CO., LTD. (KR) 2025-01-30 US claimed
US-20250034085-A1 COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION AMTIXBIO CO., LTD. (KR) 2025-01-30 US claimed
EP-4349329-A1 BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION Amtixbio Co., Ltd. (KR) 2024-04-10 EP claimed
WO-2022255801-A1 BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION (주)앰틱스바이오 2022-12-08 WO claimed
US-20250205195-A1 BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION AMTIXBIO CO., LTD. (KR) 2025-06-26 US disclosed
US-20250034082-A1 FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AMTIXBIO CO., LTD. (KR) 2025-01-30 US disclosed
US-20250034084-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS AMTIXBIO CO., LTD. (KR) 2025-01-30 US disclosed
US-20250034085-A1 COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION AMTIXBIO CO., LTD. (KR) 2025-01-30 US disclosed
US-20250034083-A1 METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES AMTIXBIO CO., LTD. (KR) 2025-01-30 US disclosed
EP-4349329-A1 BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION Amtixbio Co., Ltd. (KR) 2024-04-10 EP disclosed
WO-2022255801-A1 BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION (주)앰틱스바이오 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034083-A1 METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES BCAT2, BCAT1, DAO MAOB 134/4885ACE 411/4885PPARG 4510/4885
US-20250034082-A1 FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME PEPD, BCAT1, ANPEP MAOB 2432/4885ACE 107/4885PPARG 3020/4885
US-20250034084-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS ERG28, BCAT2, AADAT MAOB 1969/4885ACE 238/4885PPARG 3864/4885
US-20250034085-A1 COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION PEPD, PREP, ANPEP MAOB 2680/4885ACE 178/4885PPARG 4089/4885
US-20250205195-A1 BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION TSLP, IL2RA, TRPC7 MAOB 3904/4885ACE 2125/4885PPARG 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.